A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Key facts
- Where
- Calgary, Hamilton, Joliette, Markham, Moncton, Montreal, North York, Québec, Sarnia, Scarborough Village, Stoney Creek, Stouffville, Toronto, Trois-Rivières, Truro, and Vancouver, CanadaSee the 16 sites
- Phase
- Phase 3
Where in Canada
- CalgaryCalgary, CanadaTaking people
- HamiltonHamilton, CanadaTaking people
- JolietteJoliette, CanadaTaking people
- MarkhamMarkham, CanadaTaking people
- MonctonMoncton, CanadaTaking people
- MontrealMontreal, CanadaTaking people
- North YorkNorth York, CanadaTaking people
- QuébecQuébec, CanadaTaking people
- SarniaSarnia, CanadaTaking people
- Scarborough VillageScarborough Village, CanadaTaking people
- Stoney CreekStoney Creek, CanadaNo longer taking part
- StouffvilleStouffville, CanadaTaking people
- TorontoToronto, CanadaTaking people
- Trois-RivièresTrois-Rivières, CanadaTaking people
- TruroTruro, CanadaTaking people
- VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07784270
- Record updated
- 28 October 2026
- Original description
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatmentRead full original descriptionShow less
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Inclusion: Males \& females (inclusive of all gender identities) age ≥18 years; BMI ≥27 kg/m2; Diagnosed with T2DM ≥90 days prior to Screening; HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling); Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation; History of at least one self-reported unsuccessful attempt to lose body weight in lifetime.
Exclusion: Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening; Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation; Use of insulin therapy for T2DM within 3 months prior to screening; Obesity primarily caused by other endocrine disorders; Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 X ULN; AST ≥ 3.0 X ULN; TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome).